ADMINISTRATION OF H2 BLOCKERS IN NSAID INDUCED GASTROPATHY IN RATS: effect on histopathological changes in gastric,

Sachin Manocha1, Dushyant Lal2, Subramanian Venkataraman3

  • 1Department of Pharmacology, Vardhaman Mahavir Medical College and Safdarjung Hospital, New Delhi, India, Vardhaman Mahaveer Open University, Department of Pharmacology, Vardhaman Mahavir Medical College, Safdarjung Hospital, New Delhi , India.

Abstract

Insights

This study shows that combining ranitidine with diclofenac helps minimize gastric damage more effectively than combining it with nimesulide. This offers a therapeutic strategy for long-term anti-inflammatory drug use.

Area of Science:

  • Gastroenterology and Pharmacology
  • Toxicology and Pathology

Background:

  • Nonsteroidal anti-inflammatory drugs (NSAIDs) can cause gastric mucosal lesions due to their acidic nature.
  • Ranitidine, an H2 receptor antagonist, is known to be beneficial for gastric ulcers.

Purpose of the Study:

  • To evaluate the protective effects of ranitidine against NSAID-induced gastropathy.
  • To assess the impact of ranitidine and NSAIDs (diclofenac, nimesulide) on the histopathology of the stomach, kidney, and liver.

Main Methods:

  • Administration of diclofenac, nimesulide, and ranitidine at varying doses (2, 4, 6 mg/kg) daily for 14 days.
  • Monitoring of gastric parameters including volume, acidity, ulcer count, and pH.
  • Histopathological examination of stomach, kidney, and liver tissues.

Main Results:

  • NSAIDs significantly altered gastric parameters and caused histopathological damage in the stomach, liver, and kidney.
  • Ranitidine with diclofenac reversed kidney damage (glomerular basement membrane thickening), unlike ranitidine with nimesulide.
  • NSAID-induced tubular necrosis in the liver and gastric inflammation were observed, with varying effects of ranitidine combinations.

Conclusions:

  • Simultaneous administration of ranitidine with diclofenac is therapeutically beneficial.
  • This combination is more effective than ranitidine with nimesulide in minimizing gastric intolerance to diclofenac.
  • Provides a rationale for using ranitidine with diclofenac in long-term anti-inflammatory treatment.

Related Concept Videos

Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists01:28

Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists

Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
1.1K
Gastritis-II: Pathophysiology01:17

Gastritis-II: Pathophysiology

Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
1.7K
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors01:13

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
1.1K
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
1.5K
Pathophysiology of Peptic Ulcer Disease: Injurious Factors01:22

Pathophysiology of Peptic Ulcer Disease: Injurious Factors

Peptic ulcers are sores on the stomach's inner lining and the upper small intestine, which are the result of disruptions in the mucosal layer that houses parietal cells which produce gastric acid, and chief cells which secrete pepsinogen.
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds...
1.4K
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
616